Septerna (SEPN) to Release Earnings on Monday

Septerna (NASDAQ:SEPN) is expected to release its Q2 2026 results before the market opens on Monday, August 10th. Analysts expect Septerna to post earnings of ($0.4260) per share and revenue of $19.2220 million for the quarter. Interested persons can check the company’s upcoming Q2 2026 earning report for the latest details on the call scheduled for Monday, August 10, 2026 at 4:00 PM ET.

Septerna (NASDAQ:SEPN) last released its quarterly earnings results on Monday, May 11th. The company reported ($0.19) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.42) by $0.23. Septerna had a negative net margin of 49.88% and a negative return on equity of 12.72%. The company had revenue of $26.52 million during the quarter, compared to the consensus estimate of $16.98 million. On average, analysts expect Septerna to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Septerna Trading Down 1.9%

Shares of SEPN stock traded down $0.67 during midday trading on Monday, reaching $33.78. 7,627 shares of the stock were exchanged, compared to its average volume of 346,355. Septerna has a 1 year low of $10.62 and a 1 year high of $38.04. The firm has a market cap of $1.52 billion, a PE ratio of -41.70 and a beta of 2.29. The company’s 50 day moving average is $33.58 and its two-hundred day moving average is $28.61.

Insider Buying and Selling

In related news, SVP Daniel D. Long sold 3,333 shares of the firm’s stock in a transaction that occurred on Wednesday, July 1st. The shares were sold at an average price of $34.36, for a total transaction of $114,521.88. Following the completion of the sale, the senior vice president owned 96,412 shares of the company’s stock, valued at $3,312,716.32. This trade represents a 3.34% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Samira Shaikhly sold 2,178 shares of the stock in a transaction on Monday, June 29th. The shares were sold at an average price of $35.18, for a total value of $76,622.04. Following the sale, the insider owned 793 shares in the company, valued at approximately $27,897.74. This represents a 73.31% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last quarter, insiders have sold 44,494 shares of company stock worth $1,469,391. Corporate insiders own 5.80% of the company’s stock.

Hedge Funds Weigh In On Septerna

A number of institutional investors and hedge funds have recently modified their holdings of the company. Goldman Sachs Group Inc. increased its position in Septerna by 86.6% during the fourth quarter. Goldman Sachs Group Inc. now owns 2,715,129 shares of the company’s stock valued at $75,698,000 after acquiring an additional 1,260,409 shares during the last quarter. Vanguard Group Inc. increased its holdings in Septerna by 7.4% in the 3rd quarter. Vanguard Group Inc. now owns 1,518,757 shares of the company’s stock worth $28,568,000 after acquiring an additional 104,394 shares in the last quarter. ADAR1 Capital Management LLC lifted its holdings in Septerna by 38.9% during the third quarter. ADAR1 Capital Management LLC now owns 1,176,491 shares of the company’s stock valued at $22,130,000 after purchasing an additional 329,264 shares in the last quarter. First Light Asset Management LLC bought a new position in shares of Septerna in the fourth quarter worth approximately $17,308,000. Finally, VR Adviser LLC increased its stake in shares of Septerna by 13.0% in the third quarter. VR Adviser LLC now owns 610,808 shares of the company’s stock worth $11,489,000 after purchasing an additional 70,355 shares in the last quarter.

Analysts Set New Price Targets

A number of equities analysts have issued reports on SEPN shares. Truist Financial increased their price objective on Septerna from $35.00 to $43.00 and gave the stock a “buy” rating in a report on Wednesday, July 1st. Stifel Nicolaus began coverage on shares of Septerna in a research report on Friday, May 1st. They set a “buy” rating and a $43.00 price target for the company. HC Wainwright restated a “buy” rating and issued a $40.00 price objective on shares of Septerna in a report on Wednesday, July 1st. Weiss Ratings reiterated a “sell (d-)” rating on shares of Septerna in a report on Friday, July 17th. Finally, Raymond James Financial upped their price target on Septerna from $47.00 to $53.00 and gave the stock a “strong-buy” rating in a research note on Monday, June 8th. One research analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $45.89.

Septerna Company Profile

We are a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by our proprietary Native Complex Platform™. Our industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of our deep pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases. GPCRs are the largest and most diverse family of cell membrane receptors and regulate physiological processes in nearly every organ system of the human body.